

Data-powered decision making: One state's approach to improving colorectal cancer screening in underserved populations

Stephanie B Wheeler, PhD MPH Associate Professor University of North Carolina at Chapel Hill Department of Health Policy & Management Center for Health Promotion & Disease Prevention Lineberger Comprehensive Cancer Center



This presentation was supported by Cooperative Agreement Number 3 U48 DP005017-01S8 from the Centers for Disease Control and Prevention. The findings and conclusions in this presentation are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Roadmap

- The rationale
- The approach
 - Defining target areas/regions for intervention
 - Selecting and adapting interventions
 - Quantifying the expected impact of interventions for specific areas/regions
 - Implementing interventions
 - Evaluating outcomes



The rationale for CRC screening

Published OnlineFirst July 8, 2015; DOI: 10.1158/1055-9965.EPI-15-0082

Cancer Epidemiolog **Biomarkers** & Prevention

Sections

To Your Health The 3 hot spots in the U.S. with the highest colon cancer death rates


The Washington Post

Although the risk of death from colorectal cancer in the United States has dropped dramatically in recent decades, there are three "hot spots" in Appalachia and the rural South where death rates are "unnecessarily high,"

researchers said. By Lena H. Sun July 8, 2015

Hotspots for colorectal cancer





Where Can Colorectal Cancer Screening Interventions Have the Most Impact?

Rebecca L. Siegel, Liora Sahar, Anthony Robbins, and Ahmedin Jernal

Abstract

Background: Although colorectal cancer death rates in the United States have declined by half since 1970, large geographic disparities persist. Spatial identification of high-risk areas can facilitate targeted screening interventions to close this gap.

Methods: We used the Cetis-Ord Ci* statistic within ArcCIS to identify contemporary colorectal cancer "hotspots" (spatial clusters of counties with high rates) based on county-level mortality data from the national vital statistics system. Hotspots were compared with the remaining aggregated counties (non-hotspot United States) by plotting trends from 1970 to 2011 and calculating rate ratios (RR). Trends were quantified using joinpoint regression.

Results: Spatial mapping identified three distinct hotspots in the contemporary United States where colorectal cancer death rates were elevated. The highest rates were in the largest hotspot, which encompassed 94 counties in the Lower Mississippi Delta

(Arkansas (17), Illinois (16), Kentucky (3), Louisiana (6), Mississippi (27), Missouri (15), and Tennessee (10)]. During 2009 to 2011, rates here were 40% higher than the non-hotspot United States [RR, 1.40; 95% confidence interval (CI), 1.34-1.46], despite being 18% lower during 1970 to 1972 (RR, 0.82; 95% CI, 0.78-0.86). The elevated risk was similar in blacks and whites. Notably, rates among black men in the Delta increased steadily by 3.5% per year from 1970 to 1990, and have since remained unchanged. Rates in hotspots in west central Appalachia and eastern Virginia/North Carolina were 18% and 9% higher, respectively, than the non-hotspot United States during 2009 to 2011.

Conclusions: Advanced spatial analysis revealed large pockets of the United States with excessive colorectal cancer death rates. Impact: These well-defined areas warrant prioritized screening intervention. Cancer Epidemiel Biomarhers Pres: 24(8); 1151-6. \$2015 AACR.

Translating Cancer Surveillance Data Into Effective Public Health Interventions

Stephanie B. Wheeler, PhD, MPH; Ethan Basch, MD, MSc

In this issue of JAMA, Mokdad and colleagues¹ report that cancer mortality has markedly decreased in the United States over the past 30 years. Based on data from the National

The greatest value of these data lies in their potent support scientific and public health priority setting thr 3 key approaches.


The rationale for CRC screening

- Colorectal cancer (CRC) screening via colonoscopy or fecal testing (FOBT/FIT) is effective and saves lives.
- CRC screening is underused in both the U.S. (66% up to date) and N.C. (70% up to date)
- CRC screening is especially low among rural (& low income, uninsured, and minority) populations
 Decision makers need to know the most effective and efficient approach to close the gap *in specific settings*
 - Impact and efficiency of CRC screening interventions vary depending on local context
- How can healthcare systems be optimized to ensure that people receive CRC screening <u>at the lowest cost</u>?






- We know how to reduce CRC morbidity and mortality
- Yet, we are terrible at implementing what we know works





Cancer Prevention and Control Research Network:

A national effort funded by CDC and NCI to advance the science and practice of dissemination and implementation in cancer prevention and control



partners wh conduct con geographic b flagship pro

Cancer Prevention & Control Research Network of the Prevention Research Center Program

www.cpcrn.org



CPCRN Network Center Map





Evidence-Based Intervention (EBI) Modeling Impact Workgroup

Purpose:

To inform cancer screening implementation planning at practice, health system, and policy levels by integrating best available evidence into decision support models and using these models to conduct virtual comparative effectiveness research

Example Works in Progress:

- Estimate statewide effect of health insurance coverage (via Medicaid expansion and health insurance exchanges) on costs and benefits of CRC screening in vulnerable populations
- Compare EBIs for improving CRC screening for Oregon's counties and regional Coordinated Care Organizations




Why simulate?

- Mathematical simulations offer a systematic method to:
 - Incorporate a range of diverse data sources into a complex "whole system" model
 - Quantify the expected uptake and health and economic impact of implementing specific EBIs
 - Forecast outcomes over a longer time period than observed in traditional epidemiologic or experimental data
 - Evaluate uncertainty
 - Mathematical simulations can aid in:
 - Comparing specific EBIs to each other (selection and adaptation)
 - Evaluating implementation strategies
 - Selecting relevant implementation outcomes
 - Evaluating clinical/comparative effectiveness outcomes



Why simulate?





Cancer Information & Population Health Resource (CIPHR)

Key collaborators

Anne Marie Meyer

Shared resources

4 Systems developers

Chris Baggett

May Kuo

Unique linkages:

Cancer registry, multi-payer claims data (Medicare, Medicaid, private), SSI death index, BRFSS, other contextual data

6 Analysts Durham High Point Greensboro Raleigh Winston-Salem 1 program coordinator Health Care Claims: Funding >6m persons since 2003 1-U48-DP005017-01 Key pubs (>50) **NC Cancer Registry:** Meyer et al, NCMJ 100% of 2003-2013 ayetteville Wheeler et al. H&P 98 eligible nonulation /100 000 Wilmington 35 - 46 eligible population /100.000 >500,000 cases 15 - 34 eligible population /100,000 es /100,000 Wheeler et al, Medical Care. 2013 15 - 479 procedur leo - 1462 proceedur Wheeler et al, Prev Cases linked to claims: Med Reports, 2016 80% of NC cancers Number showing in each county are the number of endoscopy facilites 450,000


OHSU Center for Health Systems Effectiveness

Unique linkages:

Oregon All Payer All Claims database (Medicare, Medicaid, private insurers), other contextual data

Health Care Claims:

From 2007 for Medicare and Medicaid; 2010 for private)



Key collaborators

John McConnell Melinda Davis Stephanie Renfro

Shared resources


3 Health economists5 Statisticians3 Research assistants1 program coordinator

Funding 1-U48-DP005017-01

Key pubs (>52) McConnell et al, Health Affairs, 2017 Davis et al, J of Rural Health, 2016 Charlesworth et al, JAMA IM, 2016

CPCR

Defining target areas for intervention



Selecting and adapting evidence based interventions for local implementation

Level	Approaches
Policy	Payment model reforms (e.g., Medicaid and private insurance expansion) Access to care for uninsured (e.g., CDC-funded CRC control program)
System	 Care coordination (e.g., through medical homes, ACOs) Improving health IT infrastructure Population identification Visit-based reminders Tracking systems/registries
Provider	Provider outreach, education Quality reporting and incentives to meet screening goals
Patient/Person	Decision aids delivered at visit Patient navigation support Community outreach, education, media campaigns

Selecting and adapting evidence based interventions for local implementation

Intervention	Effect Size Base (\$)		Cost Components	
Medicaid Mailed Reminder	5%age point increase in p(screen)	\$10,000	Develop registry & content (one-time)	
		\$200 / year	Programming time	
		\$0.71 / reminder	Materials (postage, paper, ink)	
		\$3,850 / year	Mail reminders	
Endoscopy Expansion	Individually-specific predicted p(screen) based upon claims-based statistical models	\$500,000 / facility	Financial incentive to locate facility in 6 underserved areas	
Targeted Mass Media	Will reach 80% of blacks, 2%age point increase in p(screen)	\$368,000 / year	Content development (one-time)	
	Will reach 40% of non-blacks, 1%age point increase in p(screen)	\$332,000 / year	Advertising for one month	
Voucher for uninsured	500 uninsured individuals turning 50 will receive colonoscopies	\$750 / person	Voucher for colonoscopy	



Quantifying the expected impact of interventions for specific areas/regions

Durham

Endoscopy proximity RONIC DISEA RESEARCH, PRACTICE, AND HEALTH

Raleigh

Volume 14, E18

Winston-Salem

High Point

Greensboro


FEBRUARY 2017

ORIGINAL RESEARCH

Cost-Effectiveness Analysis of Four Simulated Colorectal Cancer Screening Interventions, North Carolina


Kristen Hassmiller Lich, PhD¹; David A. Cornejo²; Maria E. Mayorga, PhD²; Michael Pignone, MD, MPH^{3,4,5,6}; Florence K.L. Tangka, PhD⁷; Lisa C. Richardson, MD, MPH⁷; Tzy-Mey Kuo, PhD, MPH³; Anne-Marie Meyer, PhD^{3,8}; Ingrid J. Hall, PhD, MPH⁷; Judith Lee Smith, PhD⁷; Todd A. Durham, MS¹; Steven A. Chall, MS⁹; Trisha M. Crutchfield, MHA, MSIS^{4,6}; Stephanie B. Wheeler, PhD, MPH^{1,3,4} screening, COSL. dl IOW 100,000 200,000 300,000 400,000 0 Additional persons screened for CRC

Impact of Medicaid expansion: Expected change in disparity gap between White and African American males in the percent up-to-date with colorectal cancer screening from baseline to 2023 by NC region




Control

Medicaid Expansion (High Enrollment and Compliance)






Impact of Medicaid expansion: Differences in cumulative CRC screening and treatment cost savings per person between policy scenarios



ACA and Medicaid Expansion result in substantial long-term cost savings, especially for African American males



Implementing interventions and evaluating outcomes



What's next for the Modeling EBI workgroup?

- What would it take to get to 80% by 2018 in NC? In OR?
- How can we best integrate decision support modeling with implementation science for CRC screening?
 - To inform implementation of specific CRC screening EBIs in geographically distinct areas and populations:
 - Urban, publicly insured populations
 - Federally qualified health centers (FQHCs)
 - Coordinated Care Organizations (CCOs) in OR
 - Eastern NC
 - To develop best practices for using simulation in stakeholder implementation decision support





Multilevel predictors of colorectal cancer testing modality among publicly and privately

Stephanie B. Wheeler ^{a.b.c.d.a}, Tzy-Mey Kuo^b, Anne Marie Meyer ^{b.e}, Christa E. Martens^b, Kristen M. Hassmiller Lich^a, Florence K.L. Tangka^f, Lisa C. Richardson^f, Ingrid J. Hall^f, Judith Lee Smith^f,

Maria E. Mayorga⁸, Paul Brown^h, Trisha M. Crutchfield^{cd}, Michael P. Pignone

insured people turning 50

- Outcomes/Products
 - Increased CRC screening
 - Evidence to inform <u>value</u>

- Publications, policy briefs, white papers, presentations, etc.

- Dissemination/Implementation
 - National level: CDC, NCI, Moonshot, National CRC Roundtable
 - Provider or State level: Medicaid, CCNC, DPH, NC Roundtable





Stephanie Wheeler, UNC

Our Team



Florence Tangka, CDC



Mike Pignone, UNC



Melinda Davis, OHSU



Lisa Richardson, CDC



Kristen Hassmiller Lich, UNC



Stephanie Renfro, OHSU



Maria Mayorga, NC State



Justin Trogdon, UNC



Paul Shafer, UNC

UNC

Sarah Drier,







Siddhartha Namibar, NC State




Rachel Townsley, NC State

John McConnell, OHSU



Leah Frerichs, UNC









Relationships, Data, and Quality Improvement Infrastructure

Critical Factors when Accountable Care Organizations and Primary Care Practices Collaborate to Increase Colorectal Cancer Screening in Medicaid Members

PRESENTED BY: Melinda M. Davis, PhD, Director of Community Engaged Research, Associate Professor – Department of Family Medicine DATE: August 14, 2017 LOCATION: CDC National Cancer Conference, Atlanta, MD






Background

- Health system stakeholders are increasingly aligning as Accountable Care Organizations (ACOs) to support improved quality, experience, and controlled costs.
- Context:
 - Oregon's Coordinated Care Organizations (CCOs, Medicaid ACOs) are the single point of accountability for health care access, quality, and outcomes of Medicaid members.
 - Colorectal cancer screening is one of 18 CCO quality incentive metrics.
- **Research Questions:** How are clinics and ACOs/CCOs working together to improve care (colorectal cancer screening)? What interventions are they implementing?








Community Health Advocacy and Research Alliance (CHARA)

- Location: Columbia River Gorge (PacificSource CCO Region)
- Established with funding from the PCORI Pipeline to Proposal Award Series (2014 – 2017)
- **Goal:** Network of community members, local health leaders and researchers who can "identify, develop, and conduct health research to answer questions that matter here."

For more information: <u>davismel@ohsu.edu</u> <u>http://www.communityresearchalliance.org/</u>



CRC Testing in Oregon: **Multilevel Factors**

Overall

Commerc



Preventive Medicine Available online 13 May 2017 In Press, Accepted Manuscript - Note to users



Geographic and population-level disparities in colorectal cancer testing: A multilevel analysis of Medicaid and commercial claims data


Melinda M. Davis^{a, b,} 📥 🔤, Stephanie Renfro^{c,} 🐸, Robyn Pham^{b,} 🐸, Kristen Hassmiller Lich^{d,} 🐸, Jackilen Shannon^{e, Ma}, Gloria D. Coronado^{f, Ma}, Stephanie B. Wheeler^{d, g, h, Ma} ± Show more

https://doi.org/10.1016/j.ypmed.2017.05.001

Get rights and content



- Despite insurance, 58% had not received colorectal cancer (CRC) testing.
- CRC testing varied from 22.4% to 46.8% across Oregon's 36 counties.
- · Individual, community, and health system-level factors impacted CRC testing.
- · Counties with higher socioeconomic deprivation displayed lower CRC testing.
- · Work to increase CRC testing in targeted counties and populations is needed.
- Controlling for age, beneficiaries had greater or testing if they were female (OR 1.04, 95% CI 1. commercially insured, or urban residents (OR 1 1.21).
- Accessing primary care (OR 2.47, 95% CI 2.37 _..., _..., distance to endoscopy (OR 0.98, 95% CI 0.92-1.03) was associated with testing.




Fam Med MDs

Specialists


Malheur -Union -Curry - 27.6 Lake - 27.9 Grant - 28.5 Gilliam - 28.9 Wallowa - 29.0

			7	
	< HS Educ	< FPL	Unemployed	Uninsu
22.4 23.4 26.6	16.3 20.2	21 25.8	10.7 8.7	25. ⁻ 22
26.6	10.7	19	8.2	17.3



Medicaid

CRC Screening in Oregon's CCOs




June 23, 2016

Oregon Health Authority Office of Health Analytics

OHSU

Point Prevalence of CRC Testing in Oregon CCO Medicaid Members



Results displayed where number of cases (denominator) \geq 10.

OHSU



Methods

- Design & Setting: Observational cross case comparative study among Oregon's 16 CCOs
- Data Collection & Participant Sample:
 - CRC technical assistance consults with CCOs between June – July 2016
 - Semi-structured interviews with key stakeholders between February – August 2016
- Analysis: Fieldnotes & interview transcripts transferred to Atlas.ti and analyzed using datadriven, emergent approach



Results - Participants

- Data gathered from 14 of 16 CCOs
 - -10 CCO consultations
 - –26 key informants: state innovator agents (n=4),
 CCO leadership (n=16) and primary care practice members (n=6)
- Over 30% of the informants (n=8) worked with more than 1 CCO.



Results

- CCOs developed their strategies and infrastructure to work with clinics over time
- CCOs often started very lean: "for over a year and a half, [the CCO] didn't lease a physical office space... They held meetings in their partners' offices." (P12)
- CCOs implemented multicomponent interventions to improve CRC screening

CRC Intervention Strategy	Component	Evidence- based?*
	Client reminders	Yes
	Client incentives	Insufficient
Increase community	Small media	Yes
demand	Mass media	Insufficient
	One-on-one education	Yes
Interventions to increase	Reducing structural barriers	Yes
community access	Reducing client out- of-pocket costs	Insufficient
Interventions to increase	Provider assessment & feedback	Yes
provider delivery	Provider reminder & recall	Yes
	Provider incentives	Insufficient

* Based on the Guide to Community Preventive Services



CCO Case Examples

Regional efforts have focused on implementing incentive programs for members (\$20 Walmart gift card for returning a fecal test) and providers (\$50-\$100 when a patient completes screening). The CCO has improvement staff who leverage relationships with practices to provide education on their alternative payment method (APM) strategies, help create pop-up reminders in clinic EHRs, and provide patient gap lists. Additionally, CCO receptionists make reminder calls to patients that are due for screening.

...the CCO elected to implement a direct mail program modeled after Kaiser. CCO leadership worked with 4-5 clinics to pilot test the intervention and work out the kinks in the first year; this included learning to have clinics review member lists in advance. The program has expanded over time and recently transitioned from implementation by CCO staff to a contract with a vendor who supports material prep and distribution. The CCO also distributes money from the quality metric pool back to clinics that meet their CRC performance targets.

Results

CCOs addressed three key dimensions as they sought to improve CRC screening with regional clinics:

- 1) Establishing and building relationships
- 2) Producing and sharing data
- 3) Developing a process and infrastructure to support quality improvement (QI)



1) Establishing Relationships

Relationships and physical proximity were critical in building trust, buy-in, and shared decision making for improvement activities by CCO and clinic partners.

"...[CCO A] did not exist as an entity on the ground before ... for us in [rural] Oregon, Portland can sometimes be a million miles away...Versus [CCO B] that has a physician led organization and the community...you knew the players from that one [from the start]." (P15)



"I think that's the way we've been able to achieve anything [is by building and leveraging relationships]. It has to be a partnership with the clinic, because we really are a guest in their clinics, so you can't just go in there and tell them what to do."

- CCO Staff, P9

2) Producing and Sharing Data

Multiple CCOs focused on generating and producing actionable data to inform improvement efforts

- Some CCOs routinely, and strategically, shared data with member clinics
- Others were refining their approach

Clinics varied in their interest and ability to respond to performance data



"We have really good reporting... We have gap lists that we can produce by clinic, by provider, by measure. We know who's got the most members and clients...so that we know where to target."

-CCO Staff, P10

"...the reports that we had gotten from the CCO were not very helpful ... we would get reams of paper and about the fourth or fifth page in when three-quarters...weren't assigned to us we sort of saw them as unuseful and put them aside....

- Clinic Member, P8

3) Developing a Process and Infrastructure to Support QI

Some CCOs led regional learning collaboratives and supported improvement staff

- Clinic-based panel managers and QI leads
- CCO-level improvement staff

"[The CCO improvement staff] actually come [out here to] the clinic and say, "What do you guys need as a clinic? What can we do to help you?"...they do a lot of support for [clinic] management ...for implementation of metrics... They are really there to help operationalize [what] we need to do to show that we're giving good care....They help with data collection...They're fabulous. I couldn't ask for anything more." (P11)



Conclusions

- CCOs used multicomponent strategies to increase CRC screening
- Not all interventions had sufficient evidence, according to the Community Guide
- CCOs needed to address relationships, data, and QI infrastructure when working with clinics to increase CRC screening

 \rightarrow similar steps for other quality metrics?



Implications & Recommendations

 Health system and policy leaders must consider relationships, data, and QI infrastructure when implementing population health initiatives across diverse settings

- Understand/assess/respond to local context

-Allow prior history and experience to inform partnership goals

- Set realistic improvement targets based on local capacity

- Use and equity-based participatory implementation science approach
- Monitor for unintended consequence: increasing disparities because of focus on "larger" clinics/systems

See also, Wheeler & Davis (In Press). "Taking the Bull by the Horns": Four Principals to Align Public Health, Primary Care, and Community Efforts to Improve Rural Cancer Control. *Journal of Rural Health.*

Acknowledgements

- Co-Authors: Rose Gunn, MA; Robyn Pham, BA; Amy Wiser, MD; Kristen Hassmiller-Lich, PhD; & Stephanie B. Wheeler, PhD
- Facilitative Partners: Adrienne Mullock & Patricia Schoonmaker, MPH

Funding: Dr. Davis has received support from an AHRQ PCOR K12 (Award Number 1 K12 HS022981 01) and National Cancer Institute K07 (1K07CA211971-01A1). The project was supported by Funding Opportunity Number CMS-1G1-12-001 from the U.S Department of Health and Human Services (HSS), Centers for Medicare & Medicaid Services. This presentation was supported by CPCRN cooperative agreements 3 U48 DP005006-01S3 and 3 U48 DP005017-01S8. The content provided is solely the responsibility of the authors and do not necessarily represent the official views of these funders nor or any of their agencies.






Thank You

For more information: davismel@ohsu.edu

Community Health Advocacy and Research Alliance (CHARA) Timeline

2011: ACO rules released by DHS & Oregon HB 3650 authorized CCOs		2013: Drs Davis and Dillon brainstorn at NAPCRG	Davis K12 Awarded	Finding the Right FIT Awarded 2015:		Accountable Communities of Health Awarded; MARC evaluation	
			d m	PCORI P2P Tier II awarded. CHARA named.		2017: Sustaina- bility Transition	
0	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc	
	2012: Oregon CCOs launched, including Pacific Source Columbia Gorge		2014: PCORI P2P Tier I awarded. Research partnership formed.		2016: PCORI P2P Tier awarded PCORI and NII proposa submitte	 d. s	
22	ŏээ		Gorge employees Collective Impact Health Specialist	t re	olumbia Gor gion receive ulture of Hea	es RWJF	OHSU

CRC Screening in Oregon's





Technical Considerations: the past, present and future of simulation modeling of colorectal cancer




EDWARD P. FITTS DEPARTMENT OF INDUSTRIAL AND SYSTEMS ENGINEERING

Siddhartha Nambiar, Rachel Townsley, Maria Mayorga North Carolina State University

Kristen Hassmiller Lich, Stephanie Wheeler University of North Carolina-Chapel Hill




Background on Colorectal Cancer



CPCRN Cancer Prevention and


- In 2012 only about 65% of individuals were up-to-date with screening
- 27% had never screened
- Improving *screening rates* is a priority

Elements of CRC Simulation Models





Example Cancer Evolution Model






CRC Simulation Model Paradigms

Discrete Event Simulation Models	Support for Individual Patient Simulation (IPS).Flexibility for patient-patient, patient-environment interaction.
Markov Models	 Enumerate health states a person will experience during the course of the disease. The changes in state are described using transition diagrams very similar to flow charts.
Stochastic Microsimulation Models	 "Stochastic" - Models simulate sequences of events by drawing from distributions of probabilities or durations. "Microsimulation" - persons are moved through the model one at a time.




CRC Simulation Model- Development History



CPCRN Cancer Prevention and Control Research Network

Sample Markov Model Structure

- UCSF (University of California, San Francisco) Model - a cohort based Markov model from age 50 until death.
- Monte Carlo simulation that runs through the model 3500 times to determine approximate values for the percent of people in each state at a given time.
- Has a small probability for cancer to develop without developing from an adenoma.






V-NC Model

- Primary Simulation Objects
 - Employs an **OOS** (Object Oriented System), driven by a modelindependent database.
 - Allows for convenient modeling of causal and treatment pathways.
 - The primary object in the CRC simulation is the person.
 - The replication will be terminated when the person dies or when statistics collection ends.



MIcrosimulation SCreening ANalysis (MISCAN)

- MISCAN–Colon is a micro– simulation program, generating individual life histories.
- Uses the Monte Carlo method to simulate all events in the program.
- Possible events are birth and death of a person, adenoma incidence and transitions from one state of disease to another.





North Carolina Colorectal Cancer (NC-CRC) model

Outline-

- Designed to support decision making regarding population screening for colorectal cancer within the state of North Carolina.
- Simulates cancer incidence and mortality by stage, age and calendar year.
- The model can be used to test the effects of various interventions on life-years and costs by increasing an individual's probability of being screened for CRC.

History-

• Based significantly on the MISCAN-COLON model (Loeve et al. 1999) and the work of Subramanian and colleagues. (2005)





Expansion on other simulation models

- Applying statistical models from administrative claims data to predict the preferred screening modality of individuals and compliance with screening.
- Calibrating natural history parameters so that the incidence, age and stage of CRC diagnosis closely match registry data specific to the state of NC.
- Models insurance and allows status to change over time.
- Incorporating the effects of **population-level interventions** to increase compliance with CRC screening recommendations.




Model Structure








Elements of Models






Parameters- Output



Object Based Model Structure





Limitations and Challenges

- Model is highly data intensive.
- Meant to inform population guidelines and is based on general population trends.
- Model can end up requiring extensive computational resources.





Future of CRC Simulation Models

• Optimization algorithms to generate candidate follow-up strategies for specific patient subgroups.

Questions/Discussions/Comments?





Acknowledgements

This publication presentation was supported in part by:

- Cooperative Agreement Number U48 DP005017-01S83 from the Centers for Disease Control and Prevention and the National Cancer Institute.
- CDC SIP 11-041 "Behavioral economics of colorectal cancer screening in underserved populations" (Co-PIs: Pignone and Wheeler)
- AHRQ 1-K-12 HS019468-01 Mentored Clinical Scientists Comparative Effectiveness Development Award (PI: Weinberger; Scholar: Wheeler)
- NIH K05 CA129166 Established Investigator Award in Cancer Prevention and Control: Improving Cancer-Related Patient Decision Making (PI: Pignone)
- NC Translational and Clinical Sciences Institute Pilot Grant "Using systems science methods to improve colorectal cancer screening in North Carolina" (PI: Lich)
- CMMI-1150732 CAREER: Incorporating Patient Heterogeneity and Choice into Predictive Models of Health and Economic Outcomes". National Science Foundation (PI: Mayorga)



Additional Slides



Assumptions(MISCAN)

- Demography Assumptions
 - The life table differs per birth cohort.
 - Death from colorectal cancer and death from other causes are considered independent from each other.
- Natural History Assumptions
 - Focus on the initiation, progression and response to treatment of colorectal cancer in the model.
- Screening Assumptions
 - Focus on all aspects of screening, including compliance and operational characteristics of the screening process.



Statistical Model Description

$$logit(\pi_{ij}) = Y_{ij} = \beta_{0j} + \sum_{k} \beta_k X_{ik} + \sum_{l} \beta_l X_{jk} + \epsilon_{ij}$$
$$\pi_{ij} = \frac{e^{Y_{ij}}}{1 + e^{Y_{ij}}}$$

 π_{ij} - Probability of binary outcome (CRC Screening vs No Screen or Colonoscopy vs FOBT) for person i at county j


 $\boldsymbol{\beta}_{0j}$ - County level intercept

Xik - Person level attributes (race, gender, etc)

 X_{jk} - County level attributes (distance to endoscopy facility)




Age Cohorts Included In Model



- Age;
- Sex;
- Race (white, black, Hispanic, other);
- Smoking status (current, former, never);
- Household income (<\$25,000, \$25,000-<\$50,000, ≥\$50,000);
- Insurance status (none, private, Medicare, Medicaid, dual Medicare and Medicaid);
- Education (not complete college, completed college);
- Residential location (zip code).
- State health insurance program participation (SHEP, not a participant, participant)
- Marital status for privately insured individuals (married, unmarried, unknown)




Process flow of lesion progression






Compliance process flow

Testing process flow








USING INDIVIDUAL-BASED SIMULATION MODELING TO INTEGRATE BIG DATA AND INTERVENTION EVIDENCE TO INFORM INTERVENTION SELECTION, ADAPTATION, AND EVALUATION: AN EXAMPLE ON COLORECTAL CANCER SCREENING

PRESENTED BY: KRISTEN HASSMILLER LICH, PHD MHSA ASSISTANT PROFESSOR, UNIV OF NORTH CAROLINA AT CHAPEL HILL




HOW DO WE *TYPICALLY* SELECT EVIDENCE-BASED PRACTICES?



SO... HOW DO WE TYPICALLY SELECT EVIDENCE-BASED PRACTICES?

HTTP://GUIDES.LIBRARY.UWM.EDU/EBPTUTORIAL



SO... HOW DO WE TYPICALLY SELECT EVIDENCE-BASED PRACTICES?

HTTPS://WWW.CDC.GOV/PCD/ISSUES/2013/12_0275.HTM

www.thecommunityguide.org



WHAT WORKS Cancer Prevention and Control: Cancer Screening

Evidence-Based Interventions for Your Community

TASK FORCE FINDINGS ON CANCER SCREENING THROUGH 2011

The Community Preventive Services Task Force (Task Force) has released the following findings on what works in public health to increase breast, cervical, and colorectal cancer screening rates. These findings are compiled in The Guide to Community Preventive Services (The Community Guide) and listed in the table below. Use the findings to identify strategies and interventions you could use for your community.

INTERVENTION STRATEGY	TASK FORCE FINDING										
Increasing Breast, Cervical, and Colo	orectal Cancer S	Screening									
Client-oriented screening inte	rvention strateg	jies									
Interventions	Breast Cancer	Cervical Cancer	Colorecta Cancer								
Client reminders	•	•	•								
Client incentives											
Small media	•	•									
Mass media	♦										
Group education	•		 								
One-on-one education		•									
Reducing structural barriers											
Reducing client out-of-pocket costs	•										
Provider-oriented screening int	Provider-oriented screening intervention strategies										
Provider assessment & feedback											
Provider incentives	tems O										
Provider reminder & recall systems											
Promoting informed decision making for cancer screening		٥									


Visit the "Cancer Prevention and Control" page of The Community Guide website at www.thecommunity.guide.org/cancer to find summaries of Task Force findings and recommendations on cancer screening. Click on each topic area to find results from the systematic reviews, included studies, evidence gaps, and journal publications.

The Centers for Disease Control and Prevention provides administrative, research, and technical support for the Community Preventive Services Task Force.

Test Name	Study Design	No. of Studies	No. of Participants	Summary of Findings (Includes Consistency, Precision)	Applicability ^a	Limitations (Includes Reporting Bias)	Overall Quality
Key Question 1: Eff	ectiveness of Sc	reening ^b					
SIG	RCT	4	458 002	SIG consistently decreased CRC-specific mortality compared with no screening at 11-12 y of follow-up (IRR, 0.73; 95% CI, 0.66-0.82). Mortality benefit was limited to distal CRC.	Fair to poor. No longer widely used in the United States.	Only 1 trial evaluated more than a single round of screening. Variation in referral criteria led to differing rates of follow-up colonoscopy.	Fair to good
gFOBT, Hemoccult II	RCT	5	419966	Biennial screening with Hemoccult II compared with no screening (404 396) consistently resulted in reduction of CRC-specific mortality (ranging 9%-22% after 2-9 rounds of screening with 11-30 y of follow-up).	Poor. No longer widely used.	Variation in number of screening rounds, use of rehydrated samples, definition of "test positive," and recommended diagnostic follow-up.	Fair to good
Key Question 2: Dia	ignostic Accurac	y of Screening ^c					
Colonoscopy	Prospective diagnostic accuracy	4	4821	Comparing colonoscopy with CTC or CTC plus colonoscopy, per-person (or per-lesion) sensitivity for adenomas ≥10 mm was 89%-98%, and per-person sensitivity for adenomas ≥6 mm was 75%-93%.	Fair. Colonoscopies were conducted or supervised by "experienced" specialists.	Studies were not designed to assess diagnostic accuracy to detect cancers. Limited studies with large number of endoscopists that were applicable to community practice.	Fair to good
стс	Prospective diagnostic accuracy	9	6497	The per-person sensitivity and specificity of CTC using bowel preparation to detect adenomas ±10 mm ranged 67%-94% and 86%-98%, respectively. The per-person sensitivity and specificity to detect adenomas 26 mm ranged 73%-98% and 80%-93%, respectively. In 2 studies, sensitivity without bowel preparation to detect adenomas was lower than that of CTC protocols using bowel preparation.	Fair. Mostly single-center studies, with 33 highly trained radiologists. Current practice may use different technologies and protocols.	Studies were not designed to assess diagnostic accuracy to detect cancers. Unclear if the variation of test performance was due to differences in study design, populations, bowel preparation, CTC technology, reader experience, or reading protocols.	Fair to good


SO... HOW DO WE TYPICALLY SELECT EVIDENCE-BASED PRACTICES?

(SOURCE: COMMUNITY GUIDE AND USPSTF REPORTS)



SO... HOW DO WE TYPICALLY SELECT EVIDENCE-BASED PRACTICES?

REF: HASSMILLER LICH ET AL., PREVENTING CHRONIC DISEASE



SO... HOW DO WE TYPICALLY SELECT EVIDENCE-BASED PRACTICES?

HTTPS://WWW.CDC.GOV/PCD/ISSUES/2007/OCT/07_0025.HTM



SO... HOW DO WE TYPICALLY SELECT EVIDENCE-BASED PRACTICES?

HTTP://AZHIN.ORG/CUMMINGS/RE-AIM

HOW COULD WE LEVERAGE SIMULATION?










- Differences in the population targeted can change impact!
 - What if my population is older?
 - More racially diverse?
 - Less likely to stay insured?
 - More rural?
 - What if our state is doing a great job with a subpopulation already?
 - Medicaid screening rates are high
 - Just had a big colonoscopy initiative
 - What if an intervention requires something that isn't in place?
 - Mass media encouraging colonoscopy... but no access?
 - We address this by:
 - Projecting screening to the local population (census data is key)
 - Basing current screening estimates on local data (claims, administrative)

SIMULATION ALLOWS DECISION MAKERS TO PROJECT CURRENT SCREENING PATTERNS TO THE **LOCAL POPULATION**



SIMULATION ALLOWS DECISION MAKERS TO PROJECT **CURRENT SCREENING PATTERNS** TO THE LOCAL POPULATION

HEALTH a PLACE

Health & Place

IMPACT ON % UP-TO-DATE IN 10TH YEAR OF POLICY WINDOW BASELINE AND % AGE POINT <u>INCREASES</u> FOR EACH INTERVENTION

	Testing as usual	Mailed Reminder	Endoscopy Expansion	Mass Media	Voucher for Uninsured
Overall	53.6%	+0.3%	+0.0%	+0.4%	+0.1%
By sex					
Males	54.7%	+0.3%	+0.0%	+0.6%	+0.2%
Females	52.4%	+0.5%	+0.0%	+0.5%	+0.1%
By race					
Whites	54.7%	+0.3%	+0.0%	+0.4%	+0.1%
Blacks	51.4%	+0.9%	+0.0%	+1.4%	+0.2%
Others	47.5%	+0.5%	+0.0%	+0.4%	+0.4%
By insurance					
Private	56.2%	+0.0%	+0.0%	+0.5%	+0.0%
Medicaid	50.3%	+4.6%	+0.2%	+0.8%	+0.0%
Medicare	51.3%	+0.0%	+0.0%	+0.4%	+0.0%
Dual	44.8%	+3.5%	+0.1%	+0.7%	+0.0%
Uninsured	14.6%	+0.0%	+0.0%	+0.6%	+1.1%





Challenges:

- The "system" is big!
- ... and constantly changing
- Micro costing is difficult
- Uncertainty in evidence

THE PUZZLE OF **LOCAL** DECISION MAKING

SYSTEM MAPPING

- Many practical and systematic ways for groups to document current systems
 - Process flow diagramming to describe current or proposed practices
 - Whole system mapping to document current programs, services, initiatives
 - Asset mapping or system support mapping to elicit resources, strengths, needs



WE TYPICALLY ESTIMATE COST/IMPACT AND COMPARE


ligg kloweity a	Effect Size	Base (\$)	Cost Components	5	
Medicaid Mailed Reminder	5%age point increase in p(screen)	\$10,000	Develop registry & content (one-time)		
		\$200 / year	Programming time		
		\$0.71 / reminder	Materials (postage, paper, ink)		
1.1		\$3,850 / year	Mail reminders		
Endoscopy Expansion	Individually-specific predicted p(screen) based upon claims-based statistical models	\$500,000 / facility	Financial incentive to locate facility in 6 underserved a		
Targeted Mass Media	Will reach 80% of blacks, 2%age point increase in p(screen)	\$368,000 / year	Content devek (one-time)	NTERVENTION COST V	EFFICIENCY FRONTIER: ERSUS ADDITIONAL LIFE-
	Will reach 40% of non-blacks, 1%age point increase in p(screen)	\$332,000 / year	Advertising for month	YEARS U	P-TO-DATE
Voucher for uninsured	500 uninsured individuals turning 50 will receive colonoscopies	\$750 / person	Voucher for g	\$12,000,000	Testing as usual Mailed Reminder
	A		colonoscopy see	\$10,000,000	▲ Endoscopy Expansion
			Iover		
			ention	\$8,000,000	× Mass Media
			Cost of intervention over	\$6,000,000	Voucher for Uninsured
			ostol	\$4,000,000 * ×	Mailed reminder + Ma
				\$2,000,000	media

INSTEAD, WE CAN DISCUSS...

What Combination of Cost Multipliers & Effect Multipliers are fundable for a given willingness to pay level?

Mass Media Intervention Cost Willingness to pay (WTP)

\$3,000,000 WTP \$10









INSTEAD, WE CAN DISCUSS...


Mailed Reminder Intervention Cost Willingness to pay (WTP) \$1,619,578 WTP \$10







Reccommendation based on most Life Years UTD																															
Mass Media Co: Mailed Reminde		3,000,000 1,679,570																													
Willingness to p	10	<u>j</u> l																													
		^o	<i>n</i>										M	ailed	неп	nina	er														
		To to L	\$218,150	\$325,920	\$434,080	\$541,350	\$647,600	\$756,590	\$862,070	\$968,280	1,072,940	1,180,930	1,285,770	1,394,040	1 ,500 ,980	1,601,910	1,708,530	1,810,920	917,090	2,016,130	2,116,370	2,210,260	2,306,400	2,399,190	2,491,250	2,586,020	2,682,070	2,771,200	2,858,850	2,946,020	3,034,230
		2			÷,		¥,	63	ĕ		÷	€÷	ξ ο	÷	÷	÷.	÷	5	۵ ۲	\$2 80	\$2	\$2	\$2	\$2	5	\$2	\$2	\$2	\$2	\$2	\$3
		E E	21,815	. 6	43,408	54,135	64,760	75,659	86,207	96,828	107,294	118,093	128,577	139,404	150,098	160,191	170,853	181,092	191,709	201,613	211,637	221,026	230,640	239,919	249,125	258,602	268,207	277,120	285,885	294,602	303,423
Max Total Cos Y	/re LITD	Effect	0.2	0.3	0.4	0.5	0.6	0.7	0.8	0.9	1	1.1	1.2	1.3	1.4	1.5	1.6	1.7	1.8	1.9	2	2.1	2.2	2.3	2.4	2.5	2.6	27	2.8	29	3
\$54,350	5,435	0.	_	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MR				MR					MR		
\$125,050	12,505	0.	_	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MB				MR			MB				MB
\$221,050	22,105	0.	_	N	N	N	N	N	Ν	N	Ν	N	Ν	Ν	N	Ν	MR							MR			MB			MB	
\$350,370	35,037	0.	5 N	N	N	N	N	Ν	Ν	Ν	N	N	N	N	N	Ν	MR	MR	MR	MB	MR	MR	MB	MB							
\$507,620	50,762	0.	6 N	N	N	N	N	N	N	Ν	N	N	N	N	N	N	MR	MR	MR	MB	MR	MR	MB	MR	MB	MR	MR	MR	MR	MR	MR
\$689,530	68,953	0.	7 N	N	N	N	Ζ	Z	N	Ζ	N	N	N	N	Ν	Z	MR	ΜR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR
\$901,850	90,185	0.	_	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR	MB	MR	MB	MR								
\$1,136,140	113,614	0.	9 N	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR				MR								
\$1,398,600	139,860		<u>1 N</u>	N	N	N	N	Ν	N	Ν	N	N	N	N	N	Ν	MR		MR					MR	MR				MR	MR	MR
\$1,694,950	169,495	1.	_	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR					MR				MR			MR
\$2,024,030	202,403	1.	_	N	N	N	N	N	N	N	N	N	N	N	N	N	MR	MR	MR					MR				MR			MR
\$2,331,030	233,103	1.	_	N	N	N	N	N	N	N	N	N	N	N	N	N	MR			MR			MR			MR				MR	
\$2,606,950 \$2,899,460	260,695	1.	_	N	N	N	N N	N	N N	N	N	N	N	N	N	N				MB			MR			MR					MR
\$2,833,460 \$3,210,460	289,946 321,046	<u> </u>		N U KaKa	MM			N Kaba		N National	N Naha	N Naka	N MM	N Naha	N MM	N MM	MR MM	MR MM		MR MM				MR MM		MR MM			MR	MM	
\$3,513,470	351,347	L	7 MM		MM												MM						MM					MM MM	MM		
\$3,848,570	384,857	L	8 MM	-	MM																		MM						MM		
\$4,200,280	420,028		9 MM		MM	<u> </u>											MM						MM						MM		
\$4,554,260	455,426	<u> </u>	2 MM		MM				MM				MM				MM						MM						MM		
\$4,931,800	493,180	L	1 MM		MM		_		MM				MM				MM						MM						MM		
\$5,324,040	532,404	<u> </u>	2 MM														ΜМ												MM		
\$5,733,080	573,308		3 MM																												
\$6,155,260	615,526		4 MM																												
\$6,581,640	658,164		5 MM																												
\$6,842,500	684,250		6 MM																												
\$7,094,760	709,476	2.	7 MM	I MM	MM	ММ	MM	MM	MM	ΜМ	MM	ΜМ	MM	MM	ΜМ	MM	MM	MM	MM	MM	MM	MM	MM	MM	MM	MM	MM	ΜМ	MM	ΜМ	MM
\$7,348,660	734,866		8 MM																												
\$7,599,340	759,934	2.	9 MM	I MM	MM	ΜМ	MM	MM	MM	MM	MM	MM	MM	MМ	MМ	MM	MM	MM	MM	MМ	MM	MM	MM	MM	MM	MM	MМ	MМ	MM	ΜМ	MM
\$7,842,640	784,264		3 MM	I MM	MM	ΜМ	MM	MM	MM	MM	MM	MM	MM	MM	MM	MM	MM	MM	MM	MM	MM	MM	MM	MM	MM	MМ	MМ	MM	MM	MМ	MM







TARGET AUDIENCES

- <u>State or local public health leaders and policy makers</u> who want to know the benefits and trade-offs of public health interventions
- Organizations responsible for specifying clinical and public health practice guidelines (e.g., the US Preventive Services Task Force, the American Cancer Society, and the Centers for Disease Control and Prevention);
- State systems such as <u>health plans, accountable care</u>
 <u>organizations, or coalitions</u>
- Local systems such as <u>healthcare and hospital systems</u>, <u>large</u> <u>employers</u>, <u>Federally Qualified Health Centers</u>, <u>AHEC regions</u>
- Clinician and/or public health researchers
- Patients and patient advocates in the community





THANK YOU! klich@unc.edu



Simulation model components & data sources

